Teva Obtains $1.5 Billion Credit Line to Refinance
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, said it got a $1.5 billion credit line to refinance debt at more favorable terms.
Citigroup Inc. and HSBC Holdings Plc are coordinators and bookrunners of the three-year unsecured revolving credit, the Petah Tikva, Israel-based company said today in a statement.